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Abstract. Analytical methods for the detection of substandard and falsiﬁed medical products (SFs) are important for
public health and patient safety. Research to understand how the physical and chemical properties of SFs can be most
effectively applied to distinguish the SFs from authentic products has not yet been investigated enough. Here, we
investigated the usefulness of two analytical methods, handheld Raman spectroscopy (handheld Raman) and X-ray
computed tomography (X-ray CT), for detecting SFs among oral solid antihypertensive pharmaceutical products con-
taining candesartancilexetil as anactivepharmaceutical ingredient (API). X-rayCTvisualizedat least twodifferent typesof
falsiﬁed tablets, one containing many cracks and voids and the other containing aggregates with high electron density,
suchas from thepresenceof theheavyelements.Genericproducts thatpurported tocontain equivalent amountsofAPI to
the authentic products were discriminated from the authentic products by the handheld Raman and the different physical
structure onX-rayCT. Approach to investigate both the chemical andphysical propertieswith handheldRamanandX-ray
CT, respectively, promise the accurate discrimination of the SFs, even if their visual appearance is similar with authentic
products. We present a decision tree for investigating the authenticity of samples purporting to be authentic commercial
tablets. Our results indicate that the combination approach of visual observation, handheld Raman and X-ray CT is a
powerful strategy for nondestructive discrimination of suspect samples.
INTRODUCTION
In 2015, 128 countries were impacted by pharmaceutical
crime, including sale of substandard and falsiﬁed medicines
(SFs), and the number of incidents in the Asia Paciﬁc Region
exceeded 1,000 for the ﬁrst time.1–9 The World Health Orga-
nization and the European Commission have warned about
the danger posed to public health by SFs, and pointed out
the need for measures to detect and prevent distribution of
SFs.10–12 The term of falsiﬁedmedicinesmeans anymedicinal
product with a false representation of 1) its identity, including
packaging, labeling, name, or composition, as regard any of
the ingredients including excipients and the strength of those
ingredients; 2) its source, including manufacturer, country of
manufacture, country of origin, or marketing authorization
holder; or 3) its history, including records and documents re-
lating to the distribution channels used.12Meanwhile, the term
of substandard medicines refers to genuine medicines pro-
duced by manufacturers authorized by the relevant National
MedicinesRegulatory Authority, butwhichdonotmeet quality
speciﬁcations set out for them by the national standards.10
The U.S. Food and Drug Administration has investigated
various analytical methods to discriminate SFs from genuine
medical products.13 Nondestructive analytical technologies
that can identify and quantify active pharmaceutical ingredi-
ents (APIs) and excipients in pharmaceutical tablets include
Raman spectroscopy,14–18 near infrared spectroscopy
(NIR),19–27 X-ray diffraction,28,29 nuclear magnetic resonance
spectroscopy,30 terahertz spectroscopy,31 and chemical im-
aging with combinations of vibrational spectroscopy and
multivariate spectral analysis.22,25,27,32–35 Inparticular, Raman
spectroscopy provides sharp, characteristic spectral peaks,
and therefore Raman spectroscopy is particularly suitable for
identifying APIs and excipients in tablets. In addition, hand-
held instruments are now widely available for Raman36 and
NIR spectroscopies, and devices covering the spectral region
from ultraviolet to the infrared.13 These instruments are suit-
able for on-site inspection to detect SFs at airports and cus-
toms, and to detect substandard medicines at manufacturing
sites. Since these instruments are relatively inexpensive and
require little or no sample preparation, they are especially
suitable for use in lowandmiddle-incomecountries (LMICs).37
Further, thesemethods are nondestructive, so that specimens
found in surveys remain available for use as evidence for legal
and regulatory purposes.
Information allowing themanufacture of falsiﬁed products
is readily available. For examples, the contents of the drug
product, including the API identity and quantity, and all ex-
cipients, are stated in the drug package insert. Other perti-
nent information, such as the shape, color, specialmarkings,
and ID code can also be obtained easily from the drug
package insert or website information. Pﬁzer Inc. has re-
ported the existence of the falsiﬁedmedicines containing the
same effective ingredient as the authenticmedicine, andwith
very similar appearance to the authentic tablets, in the global
market.38 To detect such falsiﬁed products, which may be
indistinguishable from authentic products visually and
chemically, X-ray computed tomography (X-ray CT) can be
used to visualize differences in the physical structure of the
tablets, such as particle size, uniformity of granules, ﬁlm
coating thickness, and the existence of pores or voids, which
may result from differences in the manufacturing process
and conditions, or grade of additive. These are important,
because defects of physical structure can inﬂuence both
stability and dissolution properties. Further, X-ray micro-CT
is a powerful tool to observe the distribution of elements in
tablets by utilizing the difference of the electron density. For
example, the distribution of magnesium in magnesium
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stearate, an additive used as a lubricant has been visualized
by X-ray CT.39
In this study, we investigated the effectiveness of handheld
Raman spectroscopy and X-ray CT to discriminate SFs from
authentic medicines of product A (Blopress Tablets, Takeda
Pharmaceutical Company Ltd., Osaka, Japan), focusing on
antihypertensive tablets containing candesartan cilexetil as API
which is an angiotensin II receptor blocker, because they are
widely prescribed worldwide for the treatment of hypertension.
Authentic medicines were collected from Japan manufacture.
We used generic products collected in China as example of
products containing the same API but having differences in the
kind of excipients and the manufacturing process. As known
falsiﬁed tablets,weused falsiﬁed tablets from Indonesia,whose
outer packaging andpress through pack (PTP) packagingwere
verysimilarwith theauthenticmedicine, but were inconsistent
with those of authentic medicines.
EXPERIMENTAL
Three types of authentic commercial tablets of Product A
including 4, 8, and 12 mg of API, together with lactose mono-
hydrate, corn starch, maize starch, carboxymethylcellulose
calcium (ECG-505), hydroxypropyl cellulose (HPC-L), poly-
ethylene glycol 6000 (PEG 6000), and magnesium stearate
(St-Mg) were used in this study. The weight and size of the
4 mg, 8 mg, and 12 mg tablets are equivalent, as the amount
of lactose monohydrate is adjusted according to the weight
of API tomaintain a constant total weight. Tablets distributed
as generic products inChina from twodifferentmanufactures
and two falsiﬁed products discovered in Jakarta, Indonesia,
in 2011 and 2012 were also used in this study. The falsiﬁed
products were identiﬁed based on visual inspection of the
packaging (differences from the authentic product included
the color of the printed letters and the printing positions on
the surface of the aluminumblister). These falsiﬁedproducts had
been collected in different pharmacies in Jakarta, and their
distribution was reported to Forensics, Brand Protection,
and Investigations. Two types of model formulations of
falsiﬁed tablets were also prepared by physically mixing the
API and excipients, and directly compressing the mixture at
a pressure of 11 kN without a granulation process. One of
them contained the 8 mg API and lactose monohydrate to
make the same total weight as that of the authentic tablets
(T-5), and the other contained 8 mg API and all excipients in
the same proportions as in the authentic tablets (T-6).
Handheld Raman spectroscopy. All tablets were eval-
uated with a handheld Raman spectrometer (TruScan®,
Thermo Fisher Scientiﬁc, Waltham, MA), and chemical equiva-
lence between the authentic product and the other samples was
examined based on the similarity of the Raman spectra. The
Raman spectrum of the authentic tablets was registered in the
instrument as the reference spectrum, and the similarity of
the Raman spectra between the authentic tablets and test
tablets was automatically calculated and assigned the P value.
The test tablet is judged “pass” if thePvalue for similarity ismore
than 0.05 and “fail” if less than 0.05. In other words, “fail”means
that theRaman spectrumof the test sample does notmatch that
of the authentic product. The calculation algorithm for P value in
the instrument has been validated, but has not disclosed and
is designednot tobemodiﬁable.Weconﬁrmed the validity and
the accuracy of the judgment by extracting and examining the
raw data of the Raman spectra. If the device encounters a
completely different Raman spectral pattern, it stops accu-
mulating data and judges that the P value is 0.
X-ray CT and image acquisition. The X-ray micro CT
consists of a combination of a high-intensity X-ray generator
and a high-resolution X-ray camera. It is capable of observing
the three-dimensional (3D) internal structure of tablets at the
micron scale, based on the different X-ray absorptions of the
constituentmaterials. The sample isplacedona rotating stage
located between the X-ray generator and the X-ray detector.
Multiple two-dimension X-ray transmission images are
recorded at different sample-rotation angles, and are con-
verted into a three-dimensional image by a tomographic re-
construction algorithm. X-ray tomography measurements
of tablets were conducted using a high-resolution 3D X-ray
microscope (nano3DX, Rigaku, Japan). The incident X-ray was
generated using a rotating-anode generator with a molyb-
denum target operated at the tube voltage and current of
50 kV and 24 mA, respectively. The temperature was
maintained at 22–24C during data acquisition. The 2,160
lens, which allowed measurements in a 7.12 mm × 5.40 mm
ﬁeld of view with a resolution of 4.32 μm/pixel, was used.
Each CT reconstruction was conducted using 1,800 pro-
jection shots with an exposure time of 5 seconds/shot. The
analyses were done using the nano3D Calc software
(Rigaku) and Image.40
RESULTS
Figure 1 shows the appearance of each tablet. The 4 mg
authentic product A (T-1) is white scored tablets, and the
8 mg dosage strength authentic product A (T-2) is a reddish
white scored tablet. An embossed character was observed
on the surface of both authentic tablets. The generic Chi-
nese products, labeled T-3 and T-4 were white scored
tablets with no embossed character on the surface. Two
model formulation tablets, labeled T-5 and T-6, were pre-
pared by direct compression without granulation. T-5
contains 8 mg API and lactose monohydrate in an appro-
priate quantity to make tablet of the same shape and size as
the authentic product A. T-6 includes API and all excipients
in the same proportions as the authentic product A. T-5 and
FIGURE 1. Visual inspection of tablets: T-1; authentic product A
(4 mg), T-2; authentic product A (8 mg), T-3 and T-4; generic products
from different Chinese manufacturers, T-5; model formulation in-
cluding API and lactose monohydrate, obtained by direct compres-
sion, T-6; model formulation including API and the same excipients as
in the authentic product A, obtained by direct compression, T-7 and
T-8; counterfeits found in Indonesia. This ﬁgure appears in color at
www.ajtmh.org.
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T-6 were white tablets with no scored line on the surface.
The falsiﬁed products T-7 and T-8 from Indonesia, where
product A is legally marketed were reddish white scored
tablets and reddish tabletswith no scored line, respectively.
Without detailed knowledge of physical appearance of
genuine tablets, it would be difﬁcult to distinguish the fal-
siﬁed products simply by visual inspection.
The Raman spectra of tablets T-1 to T-8 were compared
with that of the authentic product. Table 1 shows the P
values and the auto-judgment results for each tablet. The
authentic product T-2 was evaluated correctly as “pass”
(P = 0.5045). Authentic tablets with a different dose of API
(4 mg, T-1), the generic tablets T-3 and T-4 from China, and
the model formulations T-5 and T-6 including same dose of
API as authentic product T-2 were also discriminated as
“pass,” although the P values were lower than that of the
authentic product T-2. The falsiﬁed products T-7 and T-8
were evaluated as “fail” based on the obvious difference of
the Raman spectra from that of the authentic product.
These results suggested that the handheld Raman tech-
nique can distinguish falsiﬁed products that are grossly
different from authentic products, but cannot discriminate
suspect samples with similar composition including an in-
sufﬁcient quantity of API.
The Raman spectra obtained with the handheld instrument
are shown in Figure 2. Samples T-1 to T-6 showed very similar
Raman spectra to that of the authentic product. The spectral
features are mainly due to the API and lactose monohydrate.
Characteristic peaks of the API that do not overlap with peaks
due to the excipientswere observed in the region from1780 to
1700 cm
_1as shown in Figure 2. The peak intensity fromAPI in
this region was reported to increase linearly with increase of
API content in the tablets.28 The Raman spectra of tablets T-1
to T-6 illustrate the difﬁculty of discriminating authenticity
correctly among compositionally similar samples based only
on chemical properties. On the other hand, the P values of the
TABLE 1
The results of handheld Raman examination of authenticity, based on the correlation of Raman spectra between test samples and the authentic
product A (8 mg).
Number Category Sample name (Active ingredient dose) P value Judgment
T-1 Authentic Product A (4 mg) 0.2332 Pass
T-2 Authentic Product A (8 mg) 0.5045 Pass
T-3 Generic Generic Product B (8 mg) from China 0.2645 Pass
T-4 Generic Genetic Product C (4 mg) from China 0.1483 Pass
T-5 Model formulation Direct compressionof API (8mg) andLactosemonohydrate 0.1348 Pass
T-6 Model formulation Direct compression of API (8 mg) and all excipients 0.1040 Pass
T-7 Falsiﬁed product Falsiﬁed Product of product A (8 mg) from Indonesia 0.0000 Fail
T-8 Falsiﬁed product Falsiﬁed Product of product A (16 mg) from Indonesia 0.0000 Fail
The result of the instrumental judgment based on the P value is also shown.
FIGURE 2. The Raman spectra of the active pharmaceutical ingredient (API), lactose monohydrate (excipient) and the tablets. The area sur-
rounded by the dashed line covers the speciﬁc peak of API that does not overlap with the peaks of excipients. Other peaks are due to excipients,
mainly from lactosemonohydrate. The Raman spectra of T-1 to T-6 including both API and lactosemonohydrate are similar, but T-7 and T-8 show
distinctly different spectra. This ﬁgure appears in color at www.ajtmh.org.
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falsiﬁed products T-7 and T-8 were 0.0000; their spectra
showed no characteristic peaks of API, and the baselines rose
from higher to lower wavelengths, suggesting the presence of
a ﬂuorescent component. Thus, falsiﬁed products that do not
contain the API can be evaluated correctly as “fail.”
Figure 3 shows the average P values calculated automati-
cally by the handheld Raman instrument with reference to the
authentic product A (8 mg), T-2. Good repeatability of the
P value was conﬁrmed using three different lots of the au-
thentic product A (8 mg) with 10 replicate measurements. The
other doses (4 mg and 12 mg) of the authentic products gave
average P values of 0.2127 and 0.2725, respectively, com-
paredwith the range of 0.5059 to 0.6768 for three different lots
of 8 mg product A. These results suggested an appropriate
criterion of the P value should be set for discriminating the
authenticity of the product A (8 mg) from falsiﬁed products.
Basedon the averageP values, aP valueof less than 0.4might
be a suitable criterion for judgment of falsiﬁed or substandard
products containing less than 50% or more than 150% API
compared with the content of the authentic product.
Next, samples T-1 to T-8 were examined by X-ray CT, as
shown in Figure 4. Uniform granule powders and white spots
were seen in images of the authentic products T-1 and T-2.
The white spots showed an elongated planar shape and were
considered to St-Mg, a known component of the authentic
tablets. Magnesium has a high electron density, and therefore
has a higher X-ray absorption than the other components, so
that St-Mg is clearly visualized in the CT image. The CT image
of generic product T-3 showed much larger granules of non-
uniform size and pores with a diameter of more than 400 nm.
Generic products T-3 and T-4 did not show evidence of the
presence of St-Mg. Generic product T-3 showed aggregates
with a diameter of 200–600 μmorder. Themodel formulations
T-5 and T-6 showed a uniform and smooth appearance, pre-
sumably due to the direct compression process without
granulation. However, the density unevenness resulting from
the lack of enough mixing process is conﬁrmed by the color
unevenness as in the black portion of the CT imaging. Also, in
the CT imaging of T-5 and T-6, the distribution of the larger
particle as seen in T-1 and T-2 are not conﬁrmed.
The images data of falsiﬁed product T-7 showed many
pores and cracks inside the tablets, suggestive of a poor
manufacturing process. The image of falsiﬁed product T-8
shows a large amount of an unknown higher speciﬁc gravity
component dispersed throughout the tablets.
DISCUSSION
Visual inspection of the appearance of a drug product is a
critical test item for detecting the falsiﬁed products. However,
in the present study, falsiﬁed products T-7 and T-8 showed a
similar color to the authentic product T-2. Thus, instrumental
methods are important to identify SFs.
Although the spectrum resolution of the handheld Raman
instrument is only about one-tenth in the comparison with the
high resolution benchtop instrument, the handheld device is
cheap and easily portable for the ﬁeld use, such as at
the airports, customs, manufacturing sites in the developing
countries, owing to its small size. This instrument covers the
required region of 2875–250 cm
_1 to observe APIs and some
excipients in the tablets. In this study, it was found that the
detection and discrimination of the falsiﬁed products of the
product A were achieved by using the handheld Raman in-
strument. Although the Raman spectra of tablets T-1 to T-6
were quite similar, the behavior of the repeatability in the same
lot and the variation of the P value among the lots suggested
FIGURE 3. AverageP valuesof authentic products calculatedautomatically by thehandheldRamandevice for similarity to theauthenticproductA
(8mg). Repeatability of theP valuewas conﬁrmedby ten replicatemeasurements. The range of theP value from themaximum to theminimumvalue
is shown by a bar. This ﬁgure appears in color at www.ajtmh.org.
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that a criterion P value of not more than 0.4 could be used to
discriminate SFs. TheP valuewas also clearly different among
the original product A, the generic products and the model
formulations. This differencemay be from the difference of the
kind of and/or the grade of the excipients and the difference
of the manufacturing process. When the suspect sample is
evaluated whether it is product A or not, the trend of the
P value should be considered.
Our results are in agreement with those of a research group
in University of Washington (Kovacs et al., 2014), which
compared various solutions for detecting SFs in LMICs and
evaluated handheld Raman as one of the top solutions, of-
fering multiple advantages, including no need for sample
preparation, high performance, speed, ease of use, low cost,
no requirement for electricity supply. Further, handheld
Raman technology can be used without opening the PTP
package, because the laser is focused on the tables, and the
peaks from the plastic do not overlap the peaks of API.
Therefore, this technology is particularly suitable for on-site
inspection throughout the supply chain, such as at custom,
posts, airports, and also in manufacturing sites.
The X-ray CT approach enables detailed examination of the
internal structure of tablets. Many voids were observed inside
the falsiﬁed product T-7, while falsiﬁed product T-8 contained
a large amount of excipients with high electron density. Also,
the physical mixture, T-5 and T-6 showed X-ray CT images
that were clearly distinct from those of authentic product A,
reﬂecting the omission of the granulation process. Further,
generic products which included the same amount of API but
contained different excipients and granules of the different
sizes could be easily distinguished. The results of X-ray CT
of T-1 and T-2 suggested that the API is not identiﬁed nor
localized in a speciﬁc location in the tablets. This is one of
the important information about the quality of T-1 and T-2
to discriminate the SFs from authentic samples. Thus, the
combination of Raman spectroscopy and X-ray CT can pro-
vide detailed information about API content and internal
structure and uniformity of the tablet. At present the CT im-
ages have to be visually evaluated, but developments in
equipment and software should make it possible to score
images objectively in the future.
Overall, these results indicate that the combination ap-
proach of visual observation, handheld Raman and X-ray CT
should be a powerful strategy for nondestructive discrimina-
tion of SFs. Figure 5 shows a decision tree for using these
combination methods to discriminate the authenticity of
samples purporting to be product A (8mg). The ﬁrst step is the
visual observation of the tablet size, shape, color, scored line,
and embossedmark (Tier 1). Next, handheldRaman should be
applied to identify the API and to detect differences of the kind
of the excipients, based on the P value (Tier 2). Generic
products and different doses of product A should be dis-
criminated at this point. Then, if necessary, the physical
composition of the tablet can be investigated by X-rayCT (Tier
3). This combination approach should enable accurate de-
tection of even falsiﬁed products that have very similar prop-
erties to the authentic products. Further it should provide
detailed information to assist in tracking the source of the
falsiﬁed products and for monitoring trends in SFs, as well as
assessing the efﬁcacy of regulatory procedure.
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